# ARTEMIDE-Gastric01 (NCT06764875)

> A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

No report yet. It can be ordered.

- Drugs tested: rilvegostomig plus trastuzumab deruxtecan
- Indication: first-line HER2-positive gastric or gastroesophageal junction cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06764875
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: HER2-positive Gastric Cancer; Gastroesophageal Junction Adenocarcinoma
- Interventions: Rilvegostomig; Trastuzumab deruxtecan; Trastuzumab; Pembrolizumab; 5-fluorouracil; Capecitabine; Cisplatin; Oxaliplatin
- Enrollment: 840
- Primary outcome: Progression free survival (PFS)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on ARTEMIDE-Gastric01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 YouTube videos
- 4 podcast episodes
- 2 posts on X

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=artemide-gastric01-nct06764875

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06764875", "email": "<work email>"}; the inbox owner confirms by the emailed link.